Diabetes Metab J.  2022 May;46(3):476-485. 10.4093/dmj.2021.0074.

Normalized Creatinine-to-Cystatin C Ratio and Risk of Diabetes in Middle-Aged and Older Adults: The China Health and Retirement Longitudinal Study

Affiliations
  • 1Institute of Diabetes, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China
  • 2Department of Endocrinology, Shenzhen People’s Hospital, The Second Clinical Medical College of Jinan University and The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China
  • 3Department of Endocrinology, Zhongda Hospital, Southeast University, Nanjing, China
  • 4Adelaide Medical School and Centre of Research Excellence (CRE) in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia

Abstract

Background
Creatinine-to-cystatin C ratio is recently suggested to be a surrogate marker for sarcopenia. However, little is known about its association with diabetes. This study aimed to fill in this gap based on a large-scale prospective cohort.
Methods
A population-based representative sample of 5,055 participants aged ≥45 years from the China Health and Retirement Longitudinal Study was enrolled between 2011 and 2012 and followed at least once during the subsequent surveys at 2013, 2015, or 2018. Creatinine-to-cystatin C ratio was calculated and normalized by body weight. Incident diabetes was ascertained by plasma glucose, glycosylated hemoglobin, self-reported history, or use of anti-diabetic drugs. Logistic regression analysis and mediation analysis were employed.
Results
During follow-up, 634 participants developed diabetes. The risk of diabetes was gradually and significantly decreased with increased normalized creatinine–cystatin C ratio. The multivariable-adjusted odds ratio for diabetes was 0.91 (95% confidence interval, 0.83 to 0.99) per 1 standard deviation higher of normalized creatinine-to-cystatin C ratio, and this relationship remained significant after controlling for muscle strength. The risk reduction in diabetes was significantly larger in participants with normal-weight and high normalized creatinine-to-cystatin C ratio compared with those with overweight/obesity and high normalized creatinine-to-cystatin C ratio (Pinteraction=0.01). Insulin resistance and inflammation appeared to be key mediators accounting for the observed relationship between normalized creatinine-to-cystatin C ratio and risk of diabetes, with their mediating effect being 93.1% and 22.0%, respectively.
Conclusion
High normalized creatinine-to-cystatin C ratio is associated with reduced risk of diabetes in middle-aged and older adults.

Keyword

Creatinine; Cystatin C; Diabetes mellitus; Insulin resistance; Longitudinal studies; Muscle strength

Figure

  • Fig. 1. Cubic spline curve for the relationship between normalized creatinine-to-cystatin C ratio and risk of diabetes. The cubic spline curve analysis was adjusted for age, gender, history of smoking and drinking, presence of hypertension, dyslipidemia, and heart disease, mean arterial pressure, glycosylated hemoglobin, total cholesterol/high-density lipoprotein, triglyceride, low-density lipoprotein, uric acid, and high-sensitivity C-reactive protein. OR, odds ratio.

  • Fig. 2. Mediation analysis for the relationship between normalized creatinine-to-cystatin C ratio and risk of diabetes. Mediation analysis (which included the tests for coefficients of a, b, and c) was conducted based on the generalized structural equation model using “GSEM” command in Stata. SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; METS-IR, the metabolic score for insulin resistance; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; eGFR, estimated glomerular filtration rate.


Reference

1. Jung CY, Joo YS, Kim HW, Han SH, Yoo TH, Kang SW, et al. Creatinine-cystatin C ratio and mortality in patients receiving intensive care and continuous kidney replacement therapy: a retrospective cohort study. Am J Kidney Dis. 2021; 77:509–16.
Article
2. Barreto EF, Poyant JO, Coville HH, Dierkhising RA, Kennedy CC, Gajic O, et al. Validation of the sarcopenia index to assess muscle mass in the critically ill: a novel application of kidney function markers. Clin Nutr. 2019; 38:1362–7.
Article
3. Fu X, Tian Z, Wen S, Sun H, Thapa S, Xiong H, et al. A new index based on serum creatinine and cystatin C is useful for assessing sarcopenia in patients with advanced cancer. Nutrition. 2021; 82:111032.
Article
4. Osaka T, Hamaguchi M, Hashimoto Y, Ushigome E, Tanaka M, Yamazaki M, et al. Decreased the creatinine to cystatin C ratio is a surrogate marker of sarcopenia in patients with type 2 diabetes. Diabetes Res Clin Pract. 2018; 139:52–8.
Article
5. Tan L, Li R, Hu X, Zhu Y, Bao T, Zuo Y, et al. Serum creatinine/cystatin C ratio as a case-finding tool for low handgrip strength in Chinese middle-aged and older adults. Sci Rep. 2020; 10:14028.
Article
6. Tabara Y, Kohara K, Okada Y, Ohyagi Y, Igase M. Creatinineto-cystatin C ratio as a marker of skeletal muscle mass in older adults: J-SHIPP study. Clin Nutr. 2020; 39:1857–62.
Article
7. Tang T, Zhuo Y, Xie L, Wang H, Yang M. Sarcopenia index based on serum creatinine and cystatin C is associated with 3-year mortality in hospitalized older patients. Sci Rep. 2020; 10:1260.
Article
8. Lee HS, Park KW, Kang J, Ki YJ, Chang M, Han JK, et al. Sarcopenia index as a predictor of clinical outcomes in older patients with coronary artery disease. J Clin Med. 2020; 9:3121.
Article
9. Komorita Y, Iwase M, Fujii H, Ide H, Ohkuma T, Jodai-Kitamura T, et al. The serum creatinine to cystatin C ratio predicts bone fracture in patients with type 2 diabetes: the Fukuoka Diabetes Registry. Diabetes Res Clin Pract. 2018; 146:202–10.
Article
10. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019; 157:107843.
Article
11. Kalyani RR, Metter EJ, Xue QL, Egan JM, Chia CW, Studenski S, et al. The relationship of lean body mass with aging to the development of diabetes. J Endocr Soc. 2020; 4:bvaa043.
Article
12. Larsen BA, Wassel CL, Kritchevsky SB, Strotmeyer ES, Criqui MH, Kanaya AM, et al. Association of muscle mass, area, and strength with incident diabetes in older adults: the Health ABC Study. J Clin Endocrinol Metab. 2016; 101:1847–55.
Article
13. Li JJ, Wittert GA, Vincent A, Atlantis E, Shi Z, Appleton SL, et al. Muscle grip strength predicts incident type 2 diabetes: population-based cohort study. Metabolism. 2016; 65:883–92.
Article
14. Ulmann G, Kai J, Durand JP, Neveux N, Jouinot A, De Bandt JP, et al. Creatinine-to-cystatin C ratio and bioelectrical impedance analysis for the assessement of low lean body mass in cancer patients: comparison to L3-computed tomography scan. Nutrition. 2021; 81:110895.
Article
15. Zhao Y, Hu Y, Smith JP, Strauss J, Yang G. Cohort profile: the China Health and Retirement Longitudinal Study (CHARLS). Int J Epidemiol. 2014; 43:61–8.
Article
16. Chen X, Crimmins E, Hu PP, Kim JK, Meng Q, Strauss J, et al. Venous blood-based biomarkers in the China Health and Retirement Longitudinal Study: rationale, design, and results from the 2015 wave. Am J Epidemiol. 2019; 188:1871–7.
Article
17. Cai X, Qiu S, Liu S, Lu Y, Luo D, Li R, et al. Body-weight fluctuation and risk of diabetes in older adults: the China Health and Retirement Longitudinal Study (CHARLS). Diabetes Res Clin Pract. 2020; 169:108419.
Article
18. Nishida K, Hashimoto Y, Kaji A, Okamura T, Sakai R, Kitagawa N, et al. Creatinine/(cystatin C × body weight) ratio is associated with skeletal muscle mass index. Endocr J. 2020; 67:733–40.
Article
19. Peterson MD, Duchowny K, Meng Q, Wang Y, Chen X, Zhao Y. Low normalized grip strength is a biomarker for cardiometabolic disease and physical disabilities among U.S. and Chinese adults. J Gerontol A Biol Sci Med Sci. 2017; 72:1525–31.
Article
20. Peterson MD, Zhang P, Choksi P, Markides KS, Al Snih S. Muscle weakness thresholds for prediction of diabetes in adults. Sports Med. 2016; 46:619–28.
Article
21. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010; 33(Suppl 1):S62–9.
22. Li DY, Yin WJ, Yi YH, Zhang BK, Zhao J, Zhu CN, et al. Development and validation of a more accurate estimating equation for glomerular filtration rate in a Chinese population. Kidney Int. 2019; 95:636–46.
Article
23. Bello-Chavolla OY, Almeda-Valdes P, Gomez-Velasco D, Viveros-Ruiz T, Cruz-Bautista I, Romo-Romo A, et al. METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes. Eur J Endocrinol. 2018; 178:533–44.
Article
24. Weng J, Ji L, Jia W, Lu J, Zhou Z, Zou D, et al. Standards of care for type 2 diabetes in China. Diabetes Metab Res Rev. 2016; 32:442–58.
Article
25. Kim BY, Won JC, Lee JH, Kim HS, Park JH, Ha KH, et al. Diabetes fact sheets in Korea, 2018: an appraisal of current status. Diabetes Metab J. 2019; 43:487–94.
Article
26. Gunzler D, Chen T, Wu P, Zhang H. Introduction to mediation analysis with structural equation modeling. Shanghai Arch Psychiatry. 2013; 25:390–4.
27. Albert JM, Geng C, Nelson S. Causal mediation analysis with a latent mediator. Biom J. 2016; 58:535–48.
Article
28. Lin YL, Chen SY, Lai YH, Wang CH, Kuo CH, Liou HH, et al. Serum creatinine to cystatin C ratio predicts skeletal muscle mass and strength in patients with non-dialysis chronic kidney disease. Clin Nutr. 2020; 39:2435–41.
Article
29. Hong S, Chang Y, Jung HS, Yun KE, Shin H, Ryu S. Relative muscle mass and the risk of incident type 2 diabetes: a cohort study. PLoS One. 2017; 12:e0188650.
Article
30. Karvonen-Gutierrez CA, Peng Q, Peterson M, Duchowny K, Nan B, Harlow S. Low grip strength predicts incident diabetes among mid-life women: the Michigan Study of Women’s Health Across the Nation. Age Ageing. 2018; 47:685–91.
Article
31. Kashani KB, Frazee EN, Kukralova L, Sarvottam K, Herasevich V, Young PM, et al. Evaluating muscle mass by using markers of kidney function: development of the sarcopenia index. Crit Care Med. 2017; 45:e23–9.
32. Tatsumi Y, Morimoto A, Asayama K, Sonoda N, Miyamatsu N, Ohno Y, et al. Risk of developing type 2 diabetes according to blood pressure levels and presence or absence of hypertensive treatment: the Saku study. Hypertens Res. 2019; 42:105–13.
Article
33. Zhang M, Liu D, Qin P, Liu Y, Sun X, Li H, et al. Association of metabolic score for insulin resistance and its 6-year change with incident type 2 diabetes mellitus. J Diabetes. 2021; 13:725–34.
Article
34. Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2013; 36:166–75.
35. Qiu S, Cai X, Yang B, Du Z, Cai M, Sun Z, et al. Association between cardiorespiratory fitness and risk of type 2 diabetes: a meta-analysis. Obesity (Silver Spring). 2019; 27:315–24.
Article
Full Text Links
  • DMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr